Cargando…
Tumour-agnostic drugs in paediatric cancers
The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case...
Autores principales: | Chisholm, Julia C., Carceller, Fernando, Marshall, Lynley V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217925/ https://www.ncbi.nlm.nih.gov/pubmed/32161367 http://dx.doi.org/10.1038/s41416-020-0770-5 |
Ejemplares similares
-
Reply to ‘Comment on “Tumour-agnostic drugs in paediatric cancers”’
por: Chisholm, Julia C., et al.
Publicado: (2020) -
Comment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020
por: Oliver, Thomas Richard William, et al.
Publicado: (2020) -
Medical domain knowledge in domain-agnostic generative AI
por: Kather, Jakob Nikolas, et al.
Publicado: (2022) -
Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations
por: Stankunaite, Reda, et al.
Publicado: (2022) -
Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer
por: Kato, Shunsuke
Publicado: (2021)